(Q57601863)
Statements
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision (English)
Joaquín Castilló
Manuel Comabella
Rosalía Horno
Ana Caminero
Carlos Nos
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference